Pacira BioSciences, Inc. (PCRX) Balance Sheet
PCRX balance sheet, 2025
December 31, 2025 · U.S. dollars$1.26B assets = $571.8M liabilities + $693.1M equity
Both columns are drawn to the same scale: what PCRX owns equals what it owes plus shareholders’ equity. Hover a block for its value.
PCRX financial health
Descriptive bands, not a rating. Fiscal 2025.
PCRX balance sheet trends, 2016–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Total assets | $391.5M2016 | $1.26B2025 | +13.9%/yr | |
| Total liabilities | $172.5M2016 | $571.8M2025 | +14.2%/yr | |
| Shareholders’ equity | $219.0M2016 | $693.1M2025 | +13.7%/yr | |
| Cash & short-term investments | $172.6M2016 | $238.4M2025 | +3.7%/yr | |
| Total debt | $108.7M2016 | $454.4M2025 | +17.2%/yr | |
| Net cash (debt) | $63.9M2016 | −$216.0M2025 | −$279.8M | |
| Working capital | $198.3M2016 | $427.4M2025 | +$229.1M | |
| Book value per share | $5.882016 | $15.392025 | +11.3%/yr | |
| Current ratio | 5.422016 | 4.542025 | −0.88 | |
| Debt / equity | 0.502016 | 0.662025 | +0.16 | |
| Shares outstanding | 37.2M2016 | 45.0M2025 | +2.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
PCRX assets
PCRX liabilities and equity
PCRX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease obligations.
PCRX balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & short-term investments | $238.4M | $484.6M | $278.6M | $288.7M | $656.4M | $521.7M | $291.9M | $383.5M | $311.3M | $172.6M |
| Cash & equivalents | $158.5M | $276.8M | $153.3M | $104.1M | $585.6M | $100.0M | $78.2M | $132.5M | $54.1M | $35.9M |
| Short-term investments | $79.9M | $207.8M | $125.3M | $184.5M | $70.8M | $421.7M | $213.7M | $250.9M | $257.2M | $136.7M |
| Receivables | $124.1M | $113.3M | $105.6M | $98.4M | $96.3M | $53.0M | $47.5M | $38.0M | $31.7M | $29.9M |
| Inventory | $152.9M | $125.3M | $104.4M | $96.1M | $98.5M | $64.7M | $58.3M | $48.6M | $41.4M | $31.3M |
| Other current assets | $32.6M | $21.9M | $21.5M | $15.2M | $14.8M | $12.3M | $10.8M | $7.9M | $6.7M | $9.3M |
| Total current assets | $548.0M | $745.1M | $510.0M | $498.3M | $866.0M | $651.6M | $408.6M | $478.0M | $391.1M | $243.1M |
| Property, plant & equipment (net) | $182.5M | $216.4M | $234.9M | $254.4M | $264.8M | $211.2M | $142.8M | $108.7M | $107.0M | $101.0M |
| Goodwill & intangible assets | $388.3M | $426.0M | $646.5M | $703.8M | $769.1M | $196.1M | $203.9M | $62.0M | $110.4M | $93.5M |
| Long-term investments | $0 | $0 | $2.4M | $64.4M | $22.0M | $109.5M | $64.8M | $25.9M | $60.0M | $0 |
| Other non-current assets | $146.2M | $166.0M | $180.5M | $160.3M | $153.4M | $106.2M | $11.0M | $14.8M | $0 | $0 |
| Total assets | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B | $831.1M | $689.4M | $628.4M | $391.5M |
| Liabilities | ||||||||||
| Accounts payable | $15.2M | $19.1M | $15.7M | $15.2M | $10.5M | $10.4M | $12.8M | $14.4M | $14.7M | $7.5M |
| Short-term debt | $9.8M | $210.7M | $17.4M | $42.8M | $382.6M | $157.1M | $4.9M | $338,000 | $324,000 | $108.7M |
| Deferred revenue | — | — | $34.0M | — | $10.1M | $71.1M | $71.8M | — | $102,000 | $595,000 |
| Total current liabilities | $120.6M | $309.9M | $97.4M | $147.8M | $521.1M | $253.3M | $107.7M | $60.7M | $56.2M | $44.8M |
| Long-term debt | $372.2M | $383.5M | $513.8M | $655.8M | $674.5M | $313.0M | $306.0M | $290.6M | $276.2M | $108.7M |
| Lease obligations | $46.0M | $53.5M | $63.6M | $73.9M | $79.6M | $78.5M | $45.9M | — | — | — |
| Other long-term liabilities | $79.0M | $81.7M | $93.1M | $102.6M | $149.3M | $88.5M | $62.4M | $16.9M | $16.5M | $18.9M |
| Total liabilities | $571.8M | $775.2M | $704.3M | $906.2M | $1.34B | $654.8M | $476.1M | $368.1M | $348.9M | $172.5M |
| Shareholders' equity | ||||||||||
| Common stock & paid-in capital | $48,000 | $47,000 | $46,000 | $46,000 | $45,000 | $44,000 | $42,000 | $41,000 | $41,000 | $37,000 |
| Retained earnings (deficit) | −$199.3M | −$206.4M | −$106.8M | −$148.8M | −$211.9M | −$253.9M | −$399.4M | −$388.2M | −$389.1M | −$346.2M |
| Treasury stock | — | — | — | — | — | — | — | — | $0 | $0 |
| Accumulated other comprehensive income | $4.3M | $343,000 | $247,000 | −$380,000 | $167,000 | $318,000 | $322,000 | −$280,000 | −$454,000 | −$30,000 |
| Minority interest | — | — | — | — | — | — | — | — | $0 | $0 |
| Total shareholders' equity | $693.1M | $778.3M | $870.1M | $775.0M | $730.4M | $619.7M | $354.9M | $321.2M | $279.5M | $219.0M |
| Key figures | ||||||||||
| Total debt | $454.4M | $638.9M | $586.0M | $763.4M | $1.13B | $541.1M | $351.9M | $290.9M | $276.5M | $108.7M |
| Net cash (debt) | −$216.0M | −$154.2M | −$307.5M | −$474.7M | −$472.4M | −$19.5M | −$60.0M | $92.5M | $34.9M | $63.9M |
| Working capital | $427.4M | $435.2M | $412.6M | $350.6M | $344.9M | $398.3M | $300.9M | $417.3M | $334.9M | $198.3M |
| Tangible book value | $304.8M | $352.4M | $223.6M | $71.2M | −$38.7M | $423.6M | $151.0M | $259.2M | $169.1M | $125.5M |
| Book value per share | $15.39 | $16.83 | $16.74 | $16.65 | $16.01 | $14.19 | $8.55 | $7.85 | $7.02 | $5.88 |
| Shares outstanding | 45.0M | 46.2M | 52.0M | 46.5M | 45.6M | 43.7M | 41.5M | 40.9M | 39.8M | 37.2M |
| Current ratio | 4.54 | 2.40 | 5.24 | 3.37 | 1.66 | 2.57 | 3.79 | 7.88 | 6.96 | 5.42 |
| Quick ratio | 3.01 | 1.93 | 3.94 | 2.62 | 1.44 | 2.27 | 3.15 | 6.95 | 6.10 | 4.52 |
| Debt / equity | 0.66 | 0.82 | 0.67 | 0.99 | 1.55 | 0.87 | 0.99 | 0.91 | 0.99 | 0.50 |
| Equity / assets | 54.8% | 50.1% | 55.3% | 46.1% | 35.2% | 48.6% | 42.7% | 46.6% | 44.5% | 55.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||
| Cash & short-term investments | $251.0M | $202.2M | $238.4M | $246.3M | $445.9M | $493.6M | $484.6M | $453.8M | $404.2M | $325.9M | $278.6M | $235.2M |
| Cash & equivalents | $205.9M | $144.3M | $158.5M | $147.6M | $300.5M | $283.6M | $276.8M | $246.0M | $247.1M | $184.1M | $153.3M | $99.1M |
| Short-term investments | $45.2M | $57.9M | $79.9M | $98.7M | $145.4M | $210.0M | $207.8M | $207.8M | $157.2M | $141.8M | $125.3M | $136.1M |
| Receivables | $132.4M | $125.6M | $124.1M | $115.5M | $114.4M | $104.7M | $113.3M | $100.7M | $104.8M | $101.6M | $105.6M | $97.0M |
| Inventory | $134.6M | $150.4M | $152.9M | $157.7M | $148.2M | $133.8M | $125.3M | $111.9M | $103.4M | $96.8M | $104.4M | $96.5M |
| Other current assets | $97.2M | $36.8M | $32.6M | $43.3M | $37.2M | $27.8M | $21.9M | $23.6M | $19.8M | $18.8M | $21.5M | $18.6M |
| Total current assets | $615.2M | $515.0M | $548.0M | $562.8M | $745.6M | $760.0M | $745.1M | $690.0M | $632.2M | $543.1M | $510.0M | $447.3M |
| Property, plant & equipment (net) | $175.2M | $175.7M | $182.5M | $191.7M | $201.7M | $213.2M | $216.4M | $220.7M | $225.1M | $230.4M | $234.9M | $239.2M |
| Goodwill & intangible assets | $305.1M | $373.0M | $388.3M | $402.7M | $442.9M | $456.5M | $426.0M | $440.3M | $617.9M | $632.2M | $646.5M | $660.8M |
| Long-term investments | $0 | $0 | $0 | $20.3M | $18.8M | $28.0M | $0 | $36.7M | $36.5M | $36.5M | $2.4M | $0 |
| Other non-current assets | $148.4M | $144.9M | $146.2M | $120.2M | $128.3M | $129.0M | $166.0M | $134.0M | $135.1M | $141.1M | $180.5M | $187.2M |
| Total assets | $1.24B | $1.21B | $1.26B | $1.30B | $1.54B | $1.59B | $1.55B | $1.52B | $1.65B | $1.58B | $1.57B | $1.53B |
| Liabilities | ||||||||||||
| Accounts payable | $17.5M | $14.0M | $15.2M | $17.7M | $30.1M | $23.2M | $19.1M | $19.4M | $18.7M | $9.0M | $15.7M | $16.5M |
| Short-term debt | $10.3M | $9.8M | $9.8M | $9.7M | $212.0M | $211.5M | $210.7M | $210.7M | $9.1M | $17.6M | $17.4M | $17.3M |
| Deferred revenue | — | — | — | — | — | — | — | — | — | — | — | −$8.6M |
| Total current liabilities | $122.0M | $108.8M | $120.6M | $107.1M | $313.2M | $314.7M | $309.9M | $306.4M | $92.7M | $93.4M | $97.4M | $93.7M |
| Long-term debt | $363.1M | $367.7M | $372.2M | $376.7M | $378.1M | $381.3M | $383.5M | $385.9M | $589.3M | $511.7M | $513.8M | $515.9M |
| Lease obligations | $49.0M | $43.5M | $46.0M | $48.6M | $50.9M | $53.1M | $53.5M | $57.1M | $59.3M | $61.4M | $63.6M | $65.7M |
| Other long-term liabilities | $86.9M | $78.2M | $79.0M | $86.6M | $88.2M | $92.1M | $81.7M | $79.8M | $85.6M | $86.0M | $93.1M | $93.3M |
| Total liabilities | $572.0M | $554.6M | $571.8M | $570.4M | $779.5M | $788.1M | $775.2M | $772.1M | $767.5M | $691.2M | $704.3M | $702.9M |
| Shareholders' equity | ||||||||||||
| Common stock & paid-in capital | $49,000 | $48,000 | $48,000 | $48,000 | $48,000 | $47,000 | $47,000 | $47,000 | $47,000 | $47,000 | $46,000 | $46,000 |
| Retained earnings (deficit) | −$191.8M | −$196.4M | −$199.3M | −$201.0M | −$206.4M | −$201.5M | −$206.4M | −$222.4M | −$78.9M | −$97.8M | −$106.8M | −$131.7M |
| Accumulated other comprehensive income | $3.2M | $3.5M | $4.3M | $4.1M | $4.1M | $1.4M | $343,000 | $678,000 | $105,000 | $152,000 | $247,000 | −$10,000 |
| Total shareholders' equity | $672.0M | $653.9M | $693.1M | $727.2M | $757.8M | $798.5M | $778.3M | $749.6M | $879.3M | $892.2M | $870.1M | $831.6M |
| Key figures | ||||||||||||
| Total debt | $412.1M | $411.2M | $454.4M | $425.3M | $631.4M | $636.5M | $638.9M | $644.4M | $648.6M | $581.8M | $586.0M | $590.3M |
| Net cash (debt) | −$161.1M | −$209.0M | −$216.0M | −$179.0M | −$185.5M | −$142.8M | −$154.2M | −$190.6M | −$244.4M | −$255.9M | −$307.5M | −$355.1M |
| Working capital | $493.2M | $406.2M | $427.4M | $455.7M | $432.4M | $445.2M | $435.2M | $383.6M | $539.5M | $449.7M | $412.6M | $353.6M |
| Tangible book value | $366.9M | $280.9M | $304.8M | $324.5M | $314.9M | $342.1M | $352.4M | $309.3M | $261.4M | $260.0M | $223.6M | $170.7M |
| Book value per share | $16.67 | $15.98 | $16.13 | $16.36 | $16.67 | $17.16 | $15.87 | $16.25 | $17.40 | $17.09 | $16.71 | $15.97 |
| Shares outstanding | 40.3M | 40.9M | 43.0M | 44.5M | 45.5M | 46.5M | 49.0M | 46.1M | 50.5M | 52.2M | 52.1M | 52.1M |
| Current ratio | 5.04 | 4.73 | 4.54 | 5.26 | 2.38 | 2.41 | 2.40 | 2.25 | 6.82 | 5.81 | 5.24 | 4.78 |
| Quick ratio | 3.14 | 3.01 | 3.01 | 3.38 | 1.79 | 1.90 | 1.93 | 1.81 | 5.49 | 4.58 | 3.94 | 3.55 |
| Debt / equity | 0.61 | 0.63 | 0.66 | 0.58 | 0.83 | 0.80 | 0.82 | 0.86 | 0.74 | 0.65 | 0.67 | 0.71 |
| Equity / assets | 54.0% | 54.1% | 54.8% | 56.0% | 49.3% | 50.3% | 50.1% | 49.3% | 53.4% | 56.3% | 55.3% | 54.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported (latest annual report filed February 26, 2026); data from EODHD.
PCRX financial position
At the end of fiscal 2025 (December 31, 2025), Pacira BioSciences had total assets of $1.3 billion (down 18.6% from a year earlier), total liabilities of $571.8 million and shareholders' equity of $693.1 million. It held $238.4 million in cash and short-term investments against $454.4 million of debt, net debt of $216.0 million. Its current ratio was 4.54. In the latest quarter (ended June 30, 2026) total assets were $1.2 billion and equity $672.0 million.
Related: PCRX income statement, PCRX cash flow statement, PCRX key metrics. See the PCRX stock overview for the latest quote and news.
PCRX balance sheet FAQ
What are Pacira BioSciences's total assets?
Pacira BioSciences reported total assets of $1.3 billion at the end of fiscal 2025 (December 31, 2025), compared with $1.6 billion a year earlier.
How much debt does Pacira BioSciences have?
Pacira BioSciences had $454.4 million of total debt at the end of fiscal 2025, including short-term borrowings and lease obligations. Its debt-to-equity ratio was 0.66.
How much cash does Pacira BioSciences have?
Pacira BioSciences held $238.4 million in cash and short-term investments at the end of fiscal 2025; with $454.4 million of debt that is net debt of $216.0 million.
What is Pacira BioSciences's book value?
Pacira BioSciences's shareholders' equity (book value) was $693.1 million at the end of fiscal 2025, or $15.39 per share.
What is Pacira BioSciences's current ratio?
Pacira BioSciences had current assets of $548.0 million and current liabilities of $120.6 million, a current ratio of 4.54 (it can cover its short-term obligations).
How much goodwill does Pacira BioSciences have?
Pacira BioSciences carried $388.3 million of goodwill and intangible assets, 30.7% of total assets, at the end of fiscal 2025.